Translating dosages from animal models to human clinical trials—revisiting body surface area scaling
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Body surface area (BSA) scaling has been used for prescribing individualized dosages of various drugs and has also been recommended by the U.S. Food and Drug Administration as one method for using data from animal model species to establish safe starting dosages for first‐in‐human clinical trials. Although BSA conversion equations have been used in certain clinical applications for decades, recent recommendations to use BSA to derive interspecies equivalents for therapeutic dosages of drug and natural products are inappropriate. A thorough review of the literature reveals that BSA conversions are based on antiquated science and have little justification in current translational medicine compared to more advanced allometric and physiologically based pharmacokinetic modeling. Misunderstood and misinterpreted use of BSA conversions may have disastrous consequences, including underdosing leading to abandonment of potentially efficacious investigational drugs, and unexpected deadly adverse events. We aim to demonstrate that recent recommendations for BSA are not appropriate for animal‐to‐human dosage conversions and use pharmacokinetic data from resveratrol studies to demonstrate how confusion between the “human equivalent dose” and “pharmacologically active dose” can lead to inappropriate dose recommendations. To optimize drug development, future recommendations for interspecies scaling must be scientifically justified using physiologic, pharmacokinetic, and toxicology data rather than simple BSA conversion.—Blanchard, O. L., Smoliga, J. M. Translating dosages from animal models to human clinical trials—revisiting body surface area scaling. FASEB J. 29, 1629‐1634 (2015). www.fasebj.org
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Concerning dosing, differences in metabolism, weight, distribution volume etc. result in different dosing, and oversimplified approaches for dose prediction are common [87].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [87]
Citations
Cites
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 10×
“62 mg/kg, or;98 mg for a 60 kg human(3, 55).”
BackgroundMethodInfluentialResveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290 · cited 3×
“(51), or any animal model study, into a human equivalent dosage for therapeutic effect.”
BackgroundLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 2×
“Reagan-Shaw’s example for the “inappropriate comparisons between studies” for pharmacologic effect in humans stemmed from the discussion of resveratrol dosage in the literatureandpress (3, 51, 52).”
BackgroundKleiber, M. (1932) · Hilgardia · doi:10.3733/hilg.v06n11p315 · Cited by 2,222 · cited 1×
“The statements by Pinkel that blood volume, circulating plasma proteins, and renal function correlated with a surface law had already been disproven in the literature for over a decade when published in 1958, and there is no reason to perpetuate misinformation by allowing it to stay in themodern literature without pro…”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Clinical Methods: The History, Physical, and Laboratory Examinations
Kruse, J. A. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450210108045 · Cited by 2,029
Quantitative Laws in Metabolism and Growth
von Bertalanffy, L. (1957) · The Quarterly Review of Biology · doi:10.1086/401873 · Cited by 2,029 · cited 4×
“The use of allometry for pharmacokinetic prediction originates from work in metabolic scaling, which plotted the formula to fit the metabolic rate and body weight of animals on double logarithmic scale (10, 29, 41).”
BackgroundMethodInfluentialHIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS
Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., & Walle, U. K. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000885 · Cited by 1,880
Kleiber, M. (1947) · Physiological Reviews · doi:10.1152/physrev.1947.27.4.511 · Cited by 1,817 · cited 8×
“In 1947, Kleiber (11) made a reductio ad absurdum argument to discredit the claims of Dreyer and Ray (18, 19), which is equally applicable to Pinkel (17) from 1958 and Reagan-Shaw et al. (3) from 2008.”
BackgroundMethodInfluentialLost in translation: animal models and clinical trials in cancer treatment.
(2014) · Europe PMC (PubMed Central) · Cited by 1,033
Research works printed but not linked: 4
- Center for Drug Evaluation and Research, 2002, Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers, Draft Guidance
- Rubner M., 1883, Über den einfluss der körpergrösse auf stoff- und kraftwechsel, Zeit. Biol., 19, 536
- Center for Drug Evaluation and Research, 2005, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers
- Mahmood I., 2005, Interspecies Pharmacokinetic Scaling: Principles and Application of Allometric Scaling
Cited by
Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Decourt, B., Lahiri, D. K., & Sabbagh, M. N. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930110551 · Cited by 371
Animal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
Sulforaphane Protects against Cardiovascular Disease via Nrf2 Activation
Bai, Y., Wang, X., Zhao, S., Ma, C., Cui, J., & Zheng, Y. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/407580 · Cited by 202
“According to the conversion formula between mice and human [87, 88], the consumption of SFN in human is supposed to be 0.”
Vitamin D, Cognition and Alzheimer’s Disease: The Therapeutic Benefit is in the D-Tails
Landel, V., Annweiler, C., Millet, P., Morello, M., & Féron, F. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150943 · Cited by 185
“Deriving interspecies equivalents for therapeutic interventions has usually been done using Body Surface Area scaling; however, it appears that this might not be as adequate as advanced allometric and physiologically based pharmacokinetic modeling for animal-to-human dosage conversion [141].”
MethodBody surface area formulae: an alarming ambiguity
Redlarski, G., Palkowski, A., & Krawczuk, M. (2016) · Scientific Reports · doi:10.1038/srep27966 · Cited by 159
Metadata
- Authors
- Blanchard, O. L., & Smoliga, J. M.
- Affiliations
- Wilmore Labs Limited Liability Company San Antonio Texas USA
- High Point University (US)
- Corresponding author
- Smoliga, James M.
- ORCID
- Smoliga, James M.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2015-02-05
- Volume
- 29
- Issue
- 5
- Pages
- 1629-1634
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2032445654
- Cited by
- 183
- References
- 61
- Citations by year
- 2026: 23 · 2025: 27 · 2024: 16 · 2023: 14 · 2022: 22 · 2021: 22 · 2020: 14 · 2019: 13 · 2018: 7 · 2017: 8 · 2016: 11 · 2015: 6
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- interspecies scaling, resveratrol, human equivalent dose, allometric scaling, physiologically based pharmacokinetic modeling, drug dosing, translational medicine, adverse drug reactions
- MeSH terms
- Animals, Body Surface Area, Clinical Trials as Topic, Dose-Response Relationship, Drug, Humans, Species Specificity, Therapeutic Equivalency, Tissue Distribution, Drugs, Investigational, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Translating dosages from animal models to human clinical trials—revisiting body surface area scaling. https://app.cochat.ai/papers/10.1096/fj.14-269043
- The paper
- Blanchard, O. L., & Smoliga, J. M. (2015). Translating dosages from animal models to human clinical trials—revisiting body surface area scaling. The FASEB Journal. https://doi.org/10.1096/fj.14-269043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.